A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events

Breast Cancer Research and Treatment

Volumn 144, Issue 3, 2014, Pages 615-624

  Addison, Christina L ^a,b,c   Bouganim, Nathaniel ^a,b   Hilton, John ^a,b   Vandermeer, Lisa ^a,b   Dent, Susan ^a,b   Amir, Eitan ^d   Hopkins, Sean ^a,b   Kuchuk, Iryna ^a,b   Segal, Roanne ^a,b   Song, Xinni ^a,b   Gertler, Stan ^a,b   Mazzarello, Sasha ^a,b   Dranitsaris, George ^a,b   Ooi, Daylily ^e   Pond, Gregory ^f   Clemons, Mark ^a,b,c  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

Biomarker; Bisphosphonate; Bone metastasis; Breast cancer; De escalated; Skeletal related event

Indexed keywords

ACTIVIN A; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; BONE SIALOPROTEIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; PAMIDRONIC ACID; PROCOLLAGEN C PROTEINASE; TRANSFORMING GROWTH FACTOR BETA;

ABNORMAL LABORATORY RESULT; ARTICLE; BONE DISEASE; BONE METASTASIS; BREAST METASTASIS; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAIN ASSESSMENT; PALLIATIVE THERAPY; PATIENT REFERRAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SELF REPORT; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE;

ADMINISTRATION, INTRAVENOUS; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; NEOPLASM METASTASIS; ODDS RATIO; PAIN; PROGNOSIS; TREATMENT OUTCOME;

EID: 84899476345     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2906-x     Document Type: Article

References (49)

1. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE (1995) A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 72(5):1289-1293
2. Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86(11):1022-1033
3. Kuchuk I, Clemons M, Addison C (2012) Time to put an end to the "one size fits all" approach to bisphosphonate use in patients with metastatic breast cancer? Curr Oncol 19(5):e303-e304. doi:10.3747/co.19.1009
4. Verma S, Kerr-Cresswell D, Dranitsaris G, Charbonneau F, Trudeau M, Yogendran G, Cesta AM, Clemons M (2004) Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists. Support Care Cancer 12(12):852-858. doi:10.1007/s00520-004-0671-9 (Pubitemid 40104780)
5. Clemons M, Enright K, Cesta A, Charbonneau F, Chow E, Warr D, Kee-Cresswell D, Chang J, Yogendran G, Trudeau M, De Angelis C, Cottrell W, Dranitsaris G (2004) Do physicians follow systemic treatment and funding policy guidelines? Can J Clin Pharmacol 11(1):e168-e178
6. Hutton B, Addison C, Mazzarello S, Joy A, Bouganim N, Fergusson D, Clemons M (2013) De-escalated administration of bone-targeted agents in patients with breast and prostate cancer: a survey of Canadian Oncologists. J Bone Oncol 2(2):77-83
7. Holen I, Coleman RE (2010) Bisphosphonates as treatment of bone metastases. Curr Pharm Des 16(11):1262-1271
8. Hortobagyi GN (2005) Moving into the future: treatment of bone metastases and beyond. Cancer Treat Rev 31(Suppl 3):9-18. doi:10.1016/j.ctrv.2005.09.003
9. Bouganim N, Clemons MJ (2011) Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block? Future Oncol 7(3):381-383. doi:10.2217/fon.10.192
10. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8):1735-1744. doi:10.1002/cncr.11701 (Pubitemid 37238631)
11. Aapro M, Saad F, Costa L (2010) Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. Oncologist 15(11):1147-1158. doi:10.1634/theoncologist.2007-0245
12. Giordano SH, Fang S, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS (2008) Use of intravenous bisphosphonates in older women with breast cancer. Oncologist 13(5):494-502. doi:10.1634/theoncologist.2007-0200 (Pubitemid 351872867)
13. Launay-Vacher V, Gligorov J, Le Tourneau C, Janus N, Spano JP, Ray-Coquard I, Oudard S, Pourrat X, Morere JF, Deray G, Beuzeboc P, Renal I, Anticancer Medications Study G (2010) Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 124(3):745-753. doi:10.1007/s10549-008-0131-1
14. Arslan C, Aksoy S, Dizdar O, Dede DS, Harputluoglu H, Altundag K (2011) Zoledronic acid and atrial fibrillation in cancer patients. Support Care Cancer 19(3):425-430. doi:10.1007/s00520-010-0868-z
15. John Camm A (2010) Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clin Ther 32(3):426-436. doi:10.1016/j.clinthera.2010.03.014
16. Wilkinson GS, Baillargeon J, Kuo YF, Freeman JL, Goodwin JS (2010) Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol 28(33):4898-4905. doi:10.1200/JCO.2010. 28.7524
17. Mariotti A (2008) Bisphosphonates and osteonecrosis of the jaws. J Dent Educ 72(8):919-929
18. Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti C (2012) ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment. J Clin Oncol 30 (suppl; abstr 9005)
19. Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti C (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14(7):663-670
20. Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M (2012) Randomized feasibility study of de-escalated (Every 12 wk) versus standard (Every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. Am J Clin Oncol. doi:10.1097/COC.0b013e3182568f7a
21. Bouganim N, Vandermeer L, Kuchuk I, Dent S, Hopkins S, Song X, Robbins D, Spencer P, Mazzarello S, Hilton J, Amir E, Dranitsaris G, Addison C, Mallick R, Clemons M (2012) Evaluating efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events. TRIUMPH: A pragmatic multicentre trial. J Cancer Res 72 (24)
22. Coleman RE, Wright J, Houston S, Agrawal R, Purohit OP-K, Hayward L, Simmonds P, Waterhouse A, Marshall H, Investigators B (2012) Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer. J Clin Oncol 30(15):511
23. NCT00424983 (2006) A prospective, randomized, double-blind, stratified, multi-center, 2-arm trial of the continued efficacy and safety of zoledronic acid (every 4 weeks vs. every 12 weeks) in patients with documented bone metastases from Breast cancer. http://clinicaltrials.gov/ct2/show/record/ NCT00320710. Accessed 23 Jan 2014
24. NCT00424983 (2009) A stratified, randomized, open-label, multicenter comparative 2-arm trial of PK, PD, and safety of zoledronic acid infusions administered monthly vs. every 3-month, in multiple myeloma patients with malignant bone lesions, and breast cancer patients with bone metastasis, who have received 9-12* doses of zoledronic acid over the prior year. http://clinicaltrials.gov/ct2/show/NCT00424983. Accessed 23 Jan 2014
25. NCT00869206 (2009) A randomized, phase III study of standard dosing versus longer dosing interval of zoledronic acid in metastatic cancer. http://www.clinicaltrials.gov/ct2/show/NCT00869206. Accessed 23 Jan 2014
26. Lipton A, Costa L, Coleman RE (2011) Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates? Breast Dis 33(2):59-69. doi:10.3233/BD-2010-0327
27. Clemons M, Dranitsaris G, Ooi W, Cole DE (2008) A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat 108(1):79-85 (Pubitemid 351623243)
28. Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE (2006) Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 24(30):4895-4900. doi:10.1200/JCO.2006.05.9212 (Pubitemid 46630917)
29. Harris K, Li K, Flynn C, Chow E (2007) Worst, average or current pain in the Brief Pain Inventory: which should be used to calculate the response to palliative radiotherapy in patients with bone metastases? Clin Oncol (R Coll Radiol) 19(7):523-527. doi:10.1016/j.clon.2007.04.007 (Pubitemid 47181184)
30. Broom R, Du H, Clemons M, Eton D, Dranitsaris G, Simmons C, Ooi W, Cella D (2009) Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain. J Pain Symptom Manag 38(2):244-257
31. Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, Carducci M (2008) TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers 13(2):217-236. doi:10.1080/13547500701676019 (Pubitemid 351250367)
32. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, Berthois Y (2006) Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer 94(2):239-246. doi:10.1038/sj.bjc.6602920 (Pubitemid 43151542)
33. Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, Rini G (2006) Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 23(2):117-122. doi:10.1007/s10585-006-9010-5 (Pubitemid 44440171)
34. Risbridger GP, Schmitt JF, Robertson DM (2001) Activins and inhibins in endocrine and other tumors. Endocr Rev 22(6):836-858 (Pubitemid 34214298)
35. Fuller K, Bayley KE, Chambers TJ (2000) Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun 268(1):2-7. doi:10.1006/bbrc.2000.2075 (Pubitemid 30116600)
36. Reis FM, Cobellis L, Tameirao LC, Anania G, Luisi S, Silva IS, Gioffre W, Di Blasio AM, Petraglia F (2002) Serum and tissue expression of activin a in postmenopausal women with breast cancer. J Clin Endocrinol Metab 87(5):2277-2282 (Pubitemid 34521520)
37. Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ (2013) Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 137(2):631-636. doi:10.1007/s10549-012- 2374-0
38. Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Luftner D (2007) The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer. Anticancer Res 27(4A):1853-1862 (Pubitemid 46954687)
39. Luftner D, Jozereau D, Schildhauer S, Geppert R, Muller C, Fiolka G, Wernecke KD, Possinger K (2005) PINP as serum marker of metastatic spread to the bone in breast cancer patients. Anticancer Res 25(3A):1491-1499 (Pubitemid 40896754)
40. Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G (1999) Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5(12):3914-3919 (Pubitemid 30013765)
41. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB (2006) The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15(1):32-38. doi:10.1158/1055-9965.EPI-05-0492
42. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23(22):4925-4935. doi:10.1200/JCO.2005.06.091 (Pubitemid 46223998)
43. Hutton B, Morretto P, Emmenegger U, Mazarello S, Kuchuk I, Addison C, Crawley F, Canil C, Malone S, Berry S, Fergusson D, Clemons M (2013) Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: a patient survey. J Bone Oncol (in press)
44. Hutton B, Addison C, Campbell K, Fergusson D, Mazarello S, Clemons M (2013) A systematic review of de-escalated versus 3-4 weekly treatment with bone targeted agents for patients with bone metastases from breast cancer. J Bone Oncol
45. Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstantinovic Z, Subota V, Ivanisevic-Milovanovic O, Nikolic-Vukosavljevic D (2003) Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer 39(4):454-461 (Pubitemid 36173689)
46. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, Turchi F, Piacentini P, Rocci L, Manavalan JS, Tonini G, Poccia F (2009) In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 58(1):31-38. doi:10.1007/s00262-008-0521-6
47. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V, Scarpa F, Roberts A, Caccamo N, Stassi G, Dieli F, Hayday AC (2010) In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 161(2):290-297. doi:10.1111/j.1365- 2249.2010.04167.x
48. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K (2010) Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 11(5):421-428. doi:10.1016/S1470- 2045(10)70054-1
49. Banys M, Solomayer EF, Gebauer G, Janni W, Krawczyk N, Lueck HJ, Becker S, Huober J, Kraemer B, Wackwitz B, Hirnle P, Wallwiener D, Fehm T (2013) Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer 13:480. doi:10.1186/1471-2407-13-480